Immune system B-cells can help predict HER2-positive breast cancer treatment response

AI nuclear energy background, future innovation of disruptive technology

Researchers at UNC Lineberger Comprehensive Cancer Center and colleagues have found that measuring activation of immune-system B cells may be better than measuring either T-cell activation or the total number of immune cells in and around a tumor, called tumor-infiltrating lymphocytes (TILs), in predicting whether HER2-positive breast cancer responds to treatment.

Pharmacotyping of childhood leukemia provides a blueprint for ‘true precision medicine’

Previous article

BMW’s i Vision Dee is a futuristic color-changing car

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Innovations